Core Viewpoint - The article discusses the recent A+ round financing of Zhiran Medical, a company specializing in invasive flexible electrode brain-machine interfaces, which raised 300 million RMB to advance clinical trials and product iterations [4][6]. Financing Overview - Zhiran Medical completed its A+ round financing on February 11, 2026, raising 300 million RMB, led by Zhongke Chuangxing, with participation from various investors including Legend Capital and IDG Capital [4][5]. - The company has a history of financing rounds, including over 300 million RMB in its A round in July 2025 and undisclosed amounts in earlier rounds [5]. Technological Advancements - The company has developed a new type of stretchable flexible electrode that addresses the core issues of traditional electrodes, such as displacement and detachment in the brain, allowing for precise and stable neural signal collection [4][15]. - This innovative technology significantly reduces mechanical damage to brain tissue, with the required stretching force being only 1/100 of that needed for traditional linear electrodes [15][12]. Product and Market Strategy - Zhiran Medical's core product is an invasive flexible brain-machine interface platform, which includes flexible electrodes, hardware systems, software, and decoding algorithms [11]. - The company aims to meet clinical needs by developing products that assist patients with paralysis, blindness, and neurological disorders [6][9]. Clinical Applications and Collaborations - The company has initiated collaborations with hospitals for clinical implantation surgeries, including a successful ultra-thin flexible deep electrode implantation in November 2024 [24]. - Zhiran Medical's digital EEG machine, capable of 1024-channel signal collection, received market approval in May 2025, catering to diverse clinical and research needs [20][21]. Production Capabilities - The company has established its own production facility for clinical-grade flexible electrodes, with a cleanroom area of nearly 2000 square meters, achieving mass production capabilities [24]. - The electrode implantation robot developed by Zhiran Medical enhances precision and efficiency in surgical procedures, reducing the time for single electrode implantation to under 30 seconds [18][19]. Future Outlook - Zhiran Medical plans to accelerate the clinical rollout of its products, with large-scale registration of over 100-channel invasive brain-machine interface products expected to start in 2026 [26]. - The long-term vision of the company is to bridge the gap between humans and machines, ultimately enhancing human brain functions [26].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into the company, Yingjixin, for misleading statements made during a Q&A session on the Shanghai Stock Exchange's interactive platform [2]. Group 1: Investigation and Compliance - The CSRC announced that it will conduct a comprehensive investigation and take legal action based on the findings to maintain healthy market development [2]. - The company has stated that it will actively cooperate with the CSRC during the investigation and will comply with relevant laws and regulations regarding information disclosure [3]. Group 2: Product Information and Market Status - Yingjixin, in collaboration with its affiliate Jingxin Weier (Changzhou) Electronics Technology Co., Ltd., has launched the IPA1299, an 8-channel low-noise design, 24-bit synchronous sampling analog-to-digital converter (ADC) chip [2]. - The IPA1299 is primarily used for electroencephalogram (EEG), electrocardiogram (ECG), and electromyogram (EMG) applications, featuring high-precision signal acquisition capabilities for non-invasive brain-computer interface (BCI) applications [2]. - The company has issued a risk warning indicating that the product is still in the market cultivation phase and has not yet achieved significant sales, thus not impacting the company's financial performance substantially [2].

Group 1 - The company has confirmed its collaboration with domestic brain-computer interface enterprises [2] - An investor inquired about potential partnerships with leading international and domestic brain-computer interface companies [2] - The response indicates a focus on domestic collaborations rather than international ones at this time [2]

Core Viewpoint - Shenzhen Injoinic Technology Co., Ltd. (referred to as "Injoinic") is under investigation by the China Securities Regulatory Commission (CSRC) for misleading statements regarding its information disclosure practices [1][2]. Group 1: Regulatory Actions - On January 6, Injoinic was found to have made misleading statements on the Shanghai Stock Exchange's E-interaction platform, leading to a CSRC investigation [1]. - The CSRC issued a notice of investigation to Injoinic on February 13, 2026, due to suspected violations of information disclosure laws [1]. - The Shanghai Stock Exchange has issued a regulatory warning to Injoinic and its responsible personnel for failing to accurately disclose the status and sales scale of its IPA1299 chip product [2][3]. Group 2: Product and Market Impact - Injoinic claimed that its IPA1299 chip, designed for high-precision measurement of human bioelectric signals, had entered mass production and could compete with leading overseas products [2]. - However, the company later clarified that the IPA1299 chip is still in the market cultivation phase and has not yet achieved significant sales, indicating uncertainty in future sales performance [2][3]. - The application of the IPA1299 chip in non-invasive brain-machine interface technology differs significantly from existing invasive technologies, highlighting a gap in technological pathways [2]. Group 3: Financial Performance - Injoinic reported a total operating revenue of 161.15 million yuan for the fiscal year 2025, representing a year-on-year increase of 12.65% [4]. - The net profit attributable to the parent company was 17.74 million yuan, reflecting a 42.81% increase compared to the previous year [4]. - The net profit after deducting non-recurring gains and losses was 16.17 million yuan, marking a 45.92% year-on-year growth [4].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Injoinic Technology Co., Ltd. (Injoinic) for misleading statements regarding its IPA1299 chip on the Shanghai Stock Exchange's E-interaction platform [1][2]. Group 1: Company Actions and Responses - On January 6, 2026, Injoinic claimed on the E-interaction platform that it had entered the brain-computer interface chip sector with its IPA1299 chip, which was said to be capable of high-precision measurement of human bioelectrical signals and had already been mass-produced [1][3]. - Following regulatory scrutiny, Injoinic clarified on January 7 that the IPA1299 chip was developed in collaboration with its affiliate, and it was still in the market cultivation phase, with no significant impact on the company's financial performance yet [1][2]. Group 2: Regulatory Findings and Market Reaction - The Shanghai Stock Exchange indicated that Injoinic's responses did not accurately reflect the product's launch entity, sales scale, and the significant technical differences from international products, leading to insufficient risk disclosure [2]. - Despite the clarification, Injoinic's stock price rose over 9% on January 7, closing at 22.48 yuan per share, an increase of 4.51% [2].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yingjixin Technology Co., Ltd. for misleading statements related to information disclosure, particularly concerning their involvement in the brain-computer interface (BCI) chip sector [1][3]. Group 1: Investigation and Regulatory Actions - The CSRC has opened a case against Yingjixin for misleading disclosures made on January 6, where the company claimed to have launched a chip for BCI applications, which was later clarified to be in the market cultivation phase and not significantly impacting company performance [1][2]. - Other companies, including Ningbo Rongbai New Energy Technology Co., Ltd. and Shenzhen Yahui Long Biotechnology Co., Ltd., have also been investigated for similar misleading disclosures, with Rongbai facing a proposed fine of 9.5 million yuan [1][4]. Group 2: Misleading Information and Market Reactions - Yingjixin's January 6 response on the Shanghai Stock Exchange's E-interaction platform was deemed misleading as it did not accurately reflect the product's launch entity, sales scale, and the significant technical differences from international products [2][3]. - Following the misleading information, Yingjixin's stock price rose by 4.51% on the day of the announcement, despite the subsequent clarification that the product was not yet commercially viable [2][3]. Group 3: Broader Industry Implications - The regulatory actions against multiple companies signal a clear stance from authorities against "hype-driven" disclosures that mislead investors, emphasizing the need for accurate and complete information [4][7]. - Companies are reminded that voluntary disclosures are not exempt from regulations, and misleading statements can lead to significant penalties and regulatory scrutiny [7].

Group 1 - The core issue involves Shenzhen Yingjixin Technology Co., Ltd. (referred to as "Yingjixin") being investigated by the China Securities Regulatory Commission (CSRC) for misleading information disclosure related to a self-questioning and answering session on the Shanghai Stock Exchange E-Interaction platform [1] - Yingjixin announced on February 13, 2026, that it received a notice of investigation from the CSRC due to suspected violations of information disclosure laws, and the company will cooperate with the investigation while continuing normal business operations [2] - The company, in collaboration with its affiliate Jingxin Weier (Changzhou) Electronic Technology Co., Ltd., has launched the IPA1299, a low-noise 8-channel 24-bit synchronous sampling analog-to-digital converter (ADC) chip, primarily used in non-invasive brain-computer interface applications [3] Group 2 - The IPA1299 chip is designed for high-precision signal acquisition, applicable in electroencephalography (EEG), electrocardiography (ECG), and electromyography (EMG), with significant technological differences from current invasive brain-computer interfaces [3] - As of the announcement date, the IPA1299 is still in the market cultivation phase for non-invasive brain-computer interfaces and has not yet achieved significant sales, indicating uncertainty in future sales performance [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 【导读】证监会对英集芯相关信息披露涉嫌误导性陈述立案调查 中国基金报记者 晨曦 又有上市公司被立案调查！ 2月13日，证监会官网发布消息称，证监会对英集芯相关信息披露涉嫌误导性陈述立案调查。 证监会指出，2026年1月6日，深圳英集芯科技股份有限公司在上证E互动平台人为策划"自问自答"，信息披露构成误导性陈述。近日，证监会已对英集芯 立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 英集芯表示，目前公司各项经营活动和业务均正常开展。在立案调查期间，公司将积极配合证监会的相关调查工作，并严格按照相关法律法规和监管要求 及时履行信息披露义务。 公开信息显示，有投资者在上证E互动上向英集芯提问："当前脑机接口市场关注度显著提升，看公司官网有应用于人体生物电信号领域的产品，希望公 司能把握这一机遇。能介绍一下公司在脑电信号采集等核心芯片方面的产品进展与后续规划吗？" 对于该问题，1月6日下午，英集芯回复称：公司通过早期投资布局，已涉足脑机接口芯片领域。公司推出的IPA1299是一款8通道、低噪声24位ADC芯 片，专用于人体生物电信号的高精度测量 ...

Market Analysis - The A-share market experienced a volume contraction and adjustment on the last trading day before the Spring Festival, with the Shanghai Composite Index falling by 1.26% to 4082.07 points, below the 4100-point mark [4] - The Shenzhen Component Index decreased by 1.28% to 14100.19 points, while the ChiNext Index dropped by 1.57% to 3275.96 points, indicating a broad market decline with 3824 stocks falling and only 1537 rising [4] - For the entire year, the Shanghai Composite Index rose by 25.28%, the Shenzhen Component Index by 38.84%, and the ChiNext Index by 58.73% [4] Sector Performance - The defense and military sector was the only one to gain, up 0.46%, driven by advancements in commercial aerospace technology and geopolitical tensions [6] - Semiconductor equipment index rose by 1.65%, benefiting from increased demand for storage chips and AI computing power [6] - The non-ferrous metals sector saw a significant decline of 3.31%, influenced by fluctuations in international precious metal prices [6] Bond Market - The bond futures market showed mixed performance, with the 30-year main contract rising by 0.04% to 112.84 yuan, while the 10-year contract fell by 0.10% to 108.505 yuan [8] - The central bank conducted a net injection of 613.5 billion yuan, leading to a significant decline in short-term interest rates [8] - The market is expected to remain confident in the central bank's moderately loose monetary policy, which may support bond market recovery [8] Commodity Market - The commodity index fell by 1.69%, with industrial products leading the decline, particularly in precious metals and energy [8] - The main crude oil contract dropped by 4.22% to 456.3 yuan per barrel, amid concerns over supply surplus [8] - Soybean prices surged to a one-year high, driven by supply-demand factors and weather conditions in Brazil [8] Investment Opportunities - The report suggests a balanced allocation in technology and consumer sectors, with a focus on sectors like photovoltaic technology, commercial aerospace, and non-ferrous metals for future growth [8][12] - The report highlights several hot investment themes, including AI applications, commercial aerospace, nuclear fusion, quantum technology, brain-machine interfaces, and robotics, indicating strong future potential [10][12]

英集芯表示，该产品用于人体生物电信号的高精度测量，其适用于各种可穿戴式设备应用场景，技术路 线与当前国际上的侵入式脑机接口存在显著技术路径差异。截至本公告披露日，该产品在非侵入式脑机 接口领域尚处于市场培育期，尚未实现规模化销售，暂未对公司业绩产生重大影响，未来销售情况存在 不确定性。 据悉，1月6日，英集芯在上证e互动平台回复提问称，公司通过早期投资布局，已涉足脑机接口芯片领 域。英集芯表示，公司推出的IPA1299是一款8通道、低噪声24位ADC芯片，专用于人体生物电信号的 高精度测量，可适用于脑电信号采集等脑机接口相关场景。IPA1299芯片已量产出货，性能参数可媲美 海外头部芯片产品。 当日晚间，上交所紧急向英集芯下发监管工作函，处理事由为关于深圳英集芯科技股份有限公司E互动 回复内容的监管工作函。 1月7日早间，英集芯公告称，其IPA1299芯片系与参股公司精芯唯尔（常州）电子科技有限公司共同推 出，是一款支持8通道低噪声设计，24位同步采样模数转换器芯片（ADC），主要应用于脑电图 （EEG）、心电图（ECG）和肌电图（EMG），该产品主要特点在于可实现高精度信号采集功能，可 应用于非侵入式脑机接 ...